🔍

WANBURY - Wanbury

📊 NSE: WANBURY 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 15:14

📢 Recent Corporate Announcements

Wanbury Gets Brazil ANVISA Approval for Sertraline Form II and Rs 15 Cr Metformin Order

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 12 Mar 2026, 09:26 AM

Wanbury Limited has received ANVISA approval from Brazil for Sertraline Form II, which complements its existing Form I approval. The company currently holds a dominant 75% market share for Sertraline in Brazil, and this new approval is expected to further consolidate its position. Additionally, the company secured approval from a major customer for a special Metformin DC grade, representing a potential revenue opportunity of Rs 15 crore per annum. Both manufacturing sites in Patalganga and Tanuku remain cGMP compliant, ensuring steady production capabilities.

Received ANVISA (Brazil) approval for Sertraline Form II to strengthen market dominance.
Currently holds a 75% market share for Sertraline in the Brazilian market.
Secured a new Metformin DC grade approval with an estimated Rs 15 crore annual business potential.
Manufacturing facilities at Patalganga and Tanuku confirmed as cGMP compliant.
Approval for Form II is expected to further consolidate the company's share of business in Brazil.

💡 Investors should note the company's strong market position in Brazil and the incremental revenue from the new Metformin order. The stock remains a positive watch for growth in the API segment and continued regulatory compliance.

Wanbury Reports Financial Turnaround: Debt Reduced by 75% and FY25 EBITDA Reaches ₹80 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 10:07 AM

Wanbury Limited has successfully executed a major financial turnaround, reducing its peak debt of ₹700 crore by approximately 75% and lowering borrowing costs from 22.5% to 12.5%. The company achieved its highest-ever operational EBITDA of ₹80 crore in FY25, driven by a dominant 30% global market share in Sertraline and 11% in Metformin. The formulations business reached financial break-even in 9MFY26, with a scale-up strategy planned for FY27. Future growth is anchored by a pipeline of four new molecule commercializations annually starting in FY27, supported by a ₹127 crore CAPEX plan for FY26-27.

Debt reduced by ~75% from peak levels with interest rates slashed from 22.5% to 12.5% effective March 2025.
Global market leadership established with a 30% share in Sertraline and 11% share in Metformin APIs.
Formulations segment achieved financial break-even in 9MFY26 after years of turnaround efforts.
Aggressive CAPEX plan of ₹64 Cr for FY26 and ₹63 Cr for FY27 focusing on new product blocks and clean rooms.
Operational EBITDA scaled approximately 3X between FY23 and FY25, reaching a record ₹80 crore.

💡 Investors should focus on the company's transition from a debt-heavy turnaround story to a growth-oriented API player with a de-risked balance sheet. Monitor the successful launch of the new anaesthetic molecule in Q4FY26 as a litmus test for the upcoming high-frequency product launch strategy.

Wanbury Limited Announces Q3 & 9M FY26 Un-audited Financial Results

🔵 WATCH ⭐ 7/10

EARNINGS 📅 06 Feb 2026, 03:08 PM

Wanbury Limited has officially released its un-audited financial results for the third quarter and nine-month period ending December 31, 2025 (FY26). The announcement was communicated via a formal press release dated February 6, 2026. This filing is a standard regulatory requirement providing transparency into the company's recent operational performance. Investors should now examine the detailed profit and loss statements to evaluate the company's growth trajectory in the pharmaceutical sector.

Release of un-audited financial results for the quarter ended December 31, 2025.
Consolidated and standalone performance for the 9-month (9M) period of FY26 included.
Official press release issued on February 6, 2026, to provide management context.
Compliance with SEBI Listing Obligations and Disclosure Requirements confirmed.

💡 Investors should review the full financial tables for specific trends in revenue and EBITDA margins. Compare the Q3 performance against previous quarters to assess if the company is maintaining its growth momentum.

Wanbury Ltd Grants 60,000 ESOPs and Allots 47,400 Equity Shares

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 07:49 PM

Wanbury Limited has announced the grant of 60,000 new stock options to employees at an exercise price of Rs. 130 per share. Concurrently, the company allotted 47,400 equity shares following the exercise of previously vested options under its 2016 ESOP plan. This allotment has increased the total paid-up share capital to Rs. 34.94 crore. The company realized a total of Rs. 4.74 lakh from the exercise of these options.

Grant of 60,000 stock options at an exercise price of Rs. 130 per share.
Allotment of 47,400 equity shares of face value Rs. 10 each.
Total paid-up share capital increased to Rs. 34,93,93,980 from Rs. 34,89,19,980.
Vesting schedule for new grants spans between 1 to 4 years based on loyalty and performance.
Realized Rs. 4.74 lakh in cash from the exercise of 47,400 options.

💡 No immediate action is required as the equity dilution from this allotment is negligible at approximately 0.14%. Investors should treat this as a routine employee retention measure.

Wanbury Ltd Allots 47,400 Shares and Grants 60,000 New ESOPs

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 07:45 PM

Wanbury Limited has announced the allotment of 47,400 equity shares to employees who exercised their vested options under the WANBURY ESOP 2016 plan. This allotment has increased the company's total paid-up share capital to Rs. 34.94 crore. Simultaneously, the Board has approved a fresh grant of 60,000 stock options at an exercise price of Rs. 130 per share. These new grants are structured with loyalty and performance-based vesting schedules spanning three to four years.

Allotment of 47,400 equity shares of Rs. 10 face value following ESOP exercise.
Total paid-up capital increased from 3,48,91,998 to 3,49,39,398 equity shares.
Grant of 60,000 new stock options at an exercise price of Rs. 130 per share.
New grants are split into Loyalty (40%) and Performance (60%) components.
Vesting for new grants ranges from 1 to 4 years from the date of grant.

💡 This is a routine corporate action with minimal equity dilution of approximately 0.14%. Investors should monitor the company's Q3 FY26 financial performance which was approved in the same board meeting.

Wanbury Approves Q3 FY26 Results, Grants 60,000 ESOPs and Allots 47,400 Shares

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 05 Feb 2026, 07:37 PM

Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter ended December 31, 2025. The company announced the grant of 60,000 new stock options to employees at an exercise price of ₹130 per share. Additionally, the board approved the allotment of 47,400 equity shares following the exercise of previously vested options, generating ₹4.74 lakh in capital. As a result, the company's total paid-up share capital has increased to ₹34.94 crore.

Approved un-audited financial results for the third quarter and nine months ended December 31, 2025
Granted 60,000 new stock options under ESOP 2016 at a pricing formula of 50% of the closing market price (₹130 per share)
Allotted 47,400 equity shares of face value ₹10 each to employees upon exercise of vested options
Total paid-up share capital increased from ₹34,89,19,980 to ₹34,93,93,980
Realized ₹4,74,000 in cash from the exercise of 47,400 options

💡 Investors should examine the detailed Q3 financial results separately to evaluate the company's fundamental performance. The current equity dilution from ESOPs is minimal and part of standard employee retention strategies.

Wanbury Approves Q3 Results, Grants 60,000 ESOPs, and Allots 47,400 Equity Shares

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 05 Feb 2026, 07:29 PM

Wanbury Limited's board met on February 5, 2026, to approve the un-audited financial results for the quarter and nine months ending December 31, 2025. The company announced a fresh grant of 60,000 stock options to employees at an exercise price of Rs. 130 per share. Additionally, the board allotted 47,400 equity shares following the exercise of vested options under the 2016 ESOP plan. This allotment has marginally increased the company's total paid-up share capital to Rs. 34.94 crore.

Approved un-audited financial results for Q3 and the nine-month period ended December 31, 2025
Granted 60,000 new ESOPs at an exercise price of Rs. 130 per share, representing 50% of the closing market price
Allotted 47,400 equity shares of Rs. 10 each, realizing Rs. 4,74,000 from the exercise of options
Total paid-up share capital increased from Rs. 34,89,19,980 to Rs. 34,93,93,980
The total number of equity shares outstanding now stands at 3,49,39,398

💡 Investors should review the detailed Q3 financial results once published to evaluate the company's fundamental performance. The current ESOP activity results in negligible equity dilution while serving as an employee retention tool.

Wanbury Achieves First Sales and Commercial Shipment of New Anaesthetic API

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 03 Feb 2026, 10:33 AM

Wanbury Limited has successfully commenced commercial shipments of its new high-demand Anaesthetic API from its Tanuku facility in Andhra Pradesh. The first sale and invoicing milestone was achieved on January 30, 2026, for a leading European customer. This move marks the company's entry into a high-growth segment just months after the initial product launch. Management expects this to signal rapid growth and production ramp-up, strengthening its global API portfolio which already serves over 50 countries.

Achieved first sales and invoicing of a new high-demand Anaesthetic API on January 30, 2026
Commenced commercial shipments to a leading European customer from the USFDA/EUGMP approved Tanuku facility
Commercialization achieved within just months of the product launch, indicating high operational efficiency
Management signals rapid growth ahead with plans to multiply production capacity and scaling fast

💡 Investors should monitor the revenue contribution from this new API in upcoming quarterly results to validate the scale of the production ramp-up. The successful entry into the specialized anaesthetic segment enhances the company's margin profile and global competitiveness.

Wanbury Launches Anaesthetic API Production; Targets ₹100 Cr+ Incremental Revenue in FY27

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 28 Jan 2026, 11:24 AM

Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. This move is expected to generate incremental revenues of approximately ₹18 crore in Q4 FY26 and over ₹100 crore in FY 2026-27. The company is also expanding its capacity with a multi-purpose intermediate block scheduled for completion by March 2026. This expansion aims to capture a share of the global market for these new APIs, which is currently valued at over ₹5,000 crore.

Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over ₹100 crore in FY 2026-27 from the new API production.
Expected immediate revenue contribution of approximately ₹18 crore in Q4 FY 2025-26.
On track to launch four additional high-value APIs (Antidiabetic, Anticoagulant, etc.) by March 2026.
Targets a global market opportunity for these molecules valued at over ₹5,000 crore.

💡 Investors should track the company's ability to scale production and meet the ₹18 crore revenue target in Q4 FY26 as a sign of execution capability. The successful launch of the additional four APIs in March 2026 could be a further re-rating trigger for the stock.

Wanbury Launches Anaesthetic API Production; Targets Rs 100 Cr+ Incremental Revenue in FY27

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 28 Jan 2026, 11:24 AM

Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. The company expects this launch to generate incremental revenues of approximately Rs. 18 crore in Q4 FY26 and over Rs. 100 crore in FY 2026-27. Furthermore, a new multi-purpose production block is on track for completion by March 2026, which will facilitate the production of four additional high-value APIs. These strategic moves target a global market opportunity valued at over Rs. 5,000 crore, significantly strengthening the company's API portfolio.

Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over Rs. 100 crore for FY 2026-27 and Rs. 18 crore for Q4 FY26.
Multi-purpose intermediate production block for four additional APIs expected to be ready by March 2026.
New products target high-value therapeutic categories including Anticoagulants and Antidepressants.
The global market for the upcoming pipeline of APIs is currently valued at over Rs. 5,000 crore.

💡 Investors should track the timely commissioning of the multi-purpose block in March 2026 and the subsequent revenue ramp-up in the coming quarters. The projected revenue growth represents a significant expansion for the company, making it a positive development for long-term shareholders.

Wanbury Ltd Submits Quarterly Share Dematerialization Compliance Certificate for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 06:02 PM

Wanbury Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending December 31, 2025. The Registrar and Share Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., confirmed that all share certificates received for dematerialization were processed, mutilated, and cancelled as per guidelines. The filing includes a detailed list of shareholders whose physical shares were converted to electronic form during the quarter. This is a standard administrative procedure ensuring the integrity of the company's share register.

Compliance certificate issued by Purva Sharegistry for the quarter ended December 31, 2025.
Confirmed that dematerialized securities are listed on the National Stock Exchange and BSE.
Detailed list shows multiple transactions, with the largest being 400 shares for a single folio on December 31, 2025.
Verification and cancellation of physical certificates were completed within prescribed SEBI timelines.

💡 This is a routine regulatory disclosure with no impact on the company's fundamentals. Investors do not need to take any action based on this announcement.

Wanbury Shareholders Approve Re-appointment of Independent Director with 99.99% Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Jan 2026, 07:26 PM

Wanbury Limited successfully passed a special resolution during its Extraordinary General Meeting (EGM) held on January 05, 2026. The resolution pertained to the re-appointment of Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director. Out of the 13,148,896 total votes polled, 13,148,070 votes (99.99%) were in favor, while only 826 votes were against. The meeting saw participation from 41 shareholders via video conferencing, representing a 37.70% turnout of the total shares.

Special Resolution for re-appointment of Mr. Manojkumar Khubchand Gursahani as Independent Director passed successfully.
99.99% of valid votes (13,148,070) were cast in favor of the resolution.
Total voter turnout represented 37.70% of the company's total equity shares.
Remote e-voting was conducted between January 02 and January 04, 2026, prior to the EGM.
The scrutinizer's report confirmed zero invalid votes were cast during the process.

💡 This is a routine governance matter ensuring board continuity; no immediate impact on the stock price is expected, and no specific action is required from investors.

Wanbury Re-appoints Manojkumar Gursahani as Independent Director for 1-Year Term

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 05 Jan 2026, 05:30 PM

Wanbury Limited has received shareholder approval to re-appoint Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director. The decision was finalized during an Extra-Ordinary General Meeting held on January 05, 2026. Mr. Gursahani will serve a one-year term effective from January 08, 2026, through January 07, 2027. This re-appointment ensures continuity in the company's independent board oversight for the upcoming year.

Re-appointment of Mr. Manojkumar Khubchand Gursahani approved by shareholders in EGM on Jan 05, 2026.
The new term is set for a duration of 1 year, starting January 08, 2026.
Mr. Gursahani is a commerce graduate and holds no familial relationship with other board directors.
The company confirmed the director is not debarred from holding office by SEBI or any other authority.

💡 This is a routine management update and does not require any immediate portfolio changes. Investors should note the relatively short one-year term which may suggest a transitional board structure.

Wanbury Shareholders Approve Re-appointment of Independent Director with 99.99% Majority

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 05 Jan 2026, 04:10 PM

Wanbury Limited's shareholders have approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as a Non-Executive Independent Director during the EGM held on January 05, 2026. The special resolution saw high consensus, with 99.99% of the 13.15 million votes cast in favor. Promoter participation was significant, contributing 13.03 million votes to the total. This approval ensures continuity in the company's board composition and governance structure.

Special resolution for re-appointment of Mr. Manojkumar Khubchand Gursahani passed with 99.99% votes in favor.
Total valid votes cast amounted to 13,148,896, with 13,148,070 in favor and 826 against.
Promoter group cast 13,029,561 votes, all of which supported the resolution.
Public institutional participation was negligible, with only 801 votes cast, all of which were against the resolution.

💡 This is a routine governance matter ensuring board stability; no immediate portfolio changes are recommended based on this announcement.

Wanbury Limited Announces Trading Window Closure Starting January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Dec 2025, 01:17 PM

Wanbury Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the announcement of the un-audited financial results for the quarter and nine months ending December 31, 2025. The specific date for the board meeting to approve these results will be communicated separately.

Trading window closure commences on January 1, 2026.
Closure pertains to the un-audited financial results for the quarter and nine months ended December 31, 2025.
Restriction applies to Directors, KMPs, Promoters, and identified employees of the company and its subsidiaries.
The window will reopen 48 hours after the financial results are officially declared to the exchanges.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals; investors should wait for the upcoming Q3 earnings announcement to assess company performance.

View All WANBURY Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

API revenue grew 8.2% YoY to INR 277 Cr in H1 FY26, while Formulations revenue grew 17.6% YoY to INR 40 Cr in H1 FY26. Total revenue for H1 FY26 was INR 323.2 Cr, up 10.57% YoY from INR 292.3 Cr.

Geographic Revenue Split

80% of revenue is derived from Exports, with 65% of that comprising regulated markets. Domestic sales contribute the remaining 20% of the total revenue mix.

Profitability Margins

Gross Margin improved from 39% in FY23 to 56.11% in H1 FY26. PAT Margin turned positive from -2.08% in FY23 to 5.28% in FY24 and reached 8.87% in H1 FY26 due to operational efficiencies and debt restructuring.

EBITDA Margin

EBITDA Margin was 15.7% in H1 FY26, a significant improvement from 4.7% in FY23. EBITDA scaled up ~3X between FY23 and FY25 through de-bottlenecking and production scale-up.

Capital Expenditure

Planned Capex of INR 64 Cr in FY25 (INR 38 Cr for new products, INR 14 Cr for de-bottlenecking) and INR 63 Cr in FY26 (INR 45 Cr for a new production block and clean rooms).

Credit Rating & Borrowing

Credit rating is IVR C+/Negative (Issuer Not Cooperating) as of October 2024. Borrowing costs were reduced from 22.5% to 12.5% effective March 1, 2025, following the exit of high-cost private financial agreements.

⚙️ Operational Drivers

Raw Materials

Key raw materials are chemical precursors for Metformin and Sertraline; COGS represented 44% of revenue in H1 FY26 (INR 142.4 Cr).

Import Sources

Not specifically disclosed in available documents, though the company exports to 50+ countries and operates in global API markets.

Capacity Expansion

Metformin capacity is 8,500 tons per year (largest manufacturer globally). Capacity for Metformin and Sertraline increased by 25% and 20% respectively over the last 3 years through de-bottlenecking.

Raw Material Costs

COGS as a % of revenue decreased from 60.7% in FY23 to 44% in H1 FY26, reflecting efficient procurement practices and technical savings.

Manufacturing Efficiency

Capacity ramp-up achieved through de-bottlenecking projects; cumulative reactor capacity stands at 386 KL across 2 USFDA approved facilities.

📈 Strategic Growth

Expected Growth Rate

10.60%

Growth Strategy

Growth will be driven by launching an Anaesthetic in Q4 FY26 and a pipeline of 4 new molecules commercialized each year starting next FY. Strategic focus includes brownfield expansion, entering China/Brazil markets, and scaling top brands in Formulations to achieve sustainable profitability by FY27.

Products & Services

API products including Metformin, Sertraline, and Anaesthetics. Branded Formulations include C Pink and Wanbury C RED.

Brand Portfolio

C Pink, Wanbury C RED.

New Products/Services

Launch of an Anaesthetic in Q4 FY26 and 4 new molecules per year starting FY27; Formulations business achieved financial break-even in H1 FY26.

Market Expansion

Expanding regulatory footprints in China (expecting approval for 1 more API) and Brazil (ANVISA approved in Dec 2024).

Market Share & Ranking

Largest manufacturer of Metformin globally with 8,500 tons/year; globally significant market share in Sertraline.

Strategic Alliances

Historical strategic alliance with Wyckoff Chemicals (US) for API manufacturing.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies; Wanbury has aligned 100% of its API portfolio to chronic segments. The company is positioned to benefit from the 10.6% growth trend seen in H1 FY26.

Competitive Landscape

Wanbury is a mid-size pharma company ranked among the Top 50 in India (ORG-IMS), competing in the global API and domestic branded formulation markets.

Competitive Moat

Moat is built on being the world's largest Metformin producer and having long-standing USFDA approvals (since 2000). This cost leadership and regulatory track record are highly sustainable due to high entry barriers in regulated API markets.

Macro Economic Sensitivity

Sensitivity to global pharmaceutical demand and regulatory changes in the US and Europe, which govern 65% of export top-line.

Consumer Behavior

Increased demand for chronic disease management (Diabetes/Metformin) is driving long-term volume growth.

Geopolitical Risks

Exposure to trade barriers in regulated markets; mitigating this by expanding into China and Brazil.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA (last inspection 2024, zero 483), EDQM (Europe), ANVISA (Brazil), and WHO GMP regulations. Compliance is mandatory for 80% of revenue derived from exports.